Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
about
Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemiaMonitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategiesRisk factors for relapse after allogeneic transplantation in acute myeloid leukemiaMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesPrognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemiaAdvancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaModulation of cell cycle by graded expression of MLL-AF4 fusion oncoproteinImatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemiaDynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro dataNPM1 deletion is associated with gross chromosomal rearrangements in leukemiaMeasurable residual disease testing in acute myeloid leukaemia.Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.An 11p15 imprinting centre region 2 deletion in a family with Beckwith Wiedemann syndrome provides insights into imprinting control at CDKN1C.Comparison of the latest commercial short and long oligonucleotide microarray technologies.Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22).Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trialHypoxia inducible factor 1alpha gene (HIF-1alpha) splice variants: potential prognostic biomarkers in breast cancer.Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemiaQuantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemiaLatent membrane protein 1 regulates STAT1 through NF-kappaB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells.RNA quantification using gold nanoprobes - application to cancer diagnosticsA sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia.Low numbers of pre-leukemic fusion genes are frequently present in umbilical cord blood without affecting DNA damage response.Cysteine and glycine-rich protein 2 (CSRP2) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics.Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet.High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia.Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion.Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemiaOutcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantationVaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseBone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone marrow microenvironment.
P2860
Q24597936-B5B66D5D-7B6A-43FC-B95F-40742039A63EQ24604850-E6C6F28D-1DBD-4546-9E26-4D7DC97E3D32Q26770394-E3A16920-488F-4059-8DB5-D0CA527B943FQ26771438-B7128701-3A8A-4075-B324-2A9F8684A954Q26828511-64342B7C-81B2-44F6-8F74-9AA984E256A8Q27006773-4748DA6C-608F-4320-BBE6-C2F50B08D8E2Q28087291-0E29EF91-B4D1-44E5-BEDF-09DD1C0D0D92Q28247462-4013C207-651A-4AD2-A967-A1E45AED16C8Q28477798-FC12CD32-E159-4E61-B668-BDF34C7ABEC9Q28478542-988C83D6-A7C0-4F63-9AEB-79DB802EFB52Q28749228-512A3BC4-4BB0-467C-B504-C34219BB56DFQ30234914-F7DE07D2-F66B-4259-9A97-8CDF46716DECQ30836557-909BC016-7513-41E2-BCD3-6944E7DFC0AEQ31044124-7AA1DBE9-2E2C-4AFC-9B99-FB43BB0F3588Q33236641-360202F7-9592-4397-93DF-8044AEDDF147Q33285468-E23E9FEA-1640-41CF-BF2F-5EAA9F1DE041Q33350395-0C4BEBF8-8472-4D8F-8300-993B91B49B46Q33412354-CAC6BF44-E258-460E-BD33-2EF8684E5CFEQ33555627-05D14110-EA9F-4E97-BD00-7472EDB69AE8Q33572303-66A39596-F02A-4434-AA19-FD494090A991Q33587563-F174B7D5-CBEA-4523-9CA5-B2E7BA47BD36Q33630831-0AEEE6B4-9D8F-42D0-8609-9EDA6AD236E9Q33632230-E81DD786-613C-45D2-9464-E6C4B0164BC1Q33660751-A473D00C-F39F-4A02-867F-B9649B2C365DQ33724152-E4003643-4E76-48F2-815E-506E513E81DFQ33748792-1A6A303D-D08C-40CA-A5AB-D1FB3B7E4CCDQ33822032-743F0905-DDD2-4951-B20B-C3CB24123684Q33829079-8A68C5CD-B45C-4A91-989E-B0DDE45061C2Q33829117-E6582971-FEC9-4DE3-B80F-9EDD3EAE9C65Q33829330-B6894B20-3FFB-4436-8266-75FDF8BE03E7Q33829373-060B0DBD-406A-48F2-9D42-AC8919053D39Q33873297-F19502E9-9E86-44BF-8FB9-C8AB954ED224Q33886162-1240B806-0284-41A8-85F2-9AB102640589Q33889952-EAFC1272-B0CC-4F76-83DD-76541AE98F7EQ33908547-BE76CA31-90C0-4F56-B558-E30BDDA49F4AQ33947104-D3D8CB96-2201-4D9F-BC8B-C4AAC4CC957CQ33956085-0A5232CF-8E1C-4E1B-8E0E-B817B9ACEF73Q34022415-AD923F68-EAFB-4B92-8471-B8E991961D76Q34032263-8DD142D8-FB11-4244-B3E2-D356C2B2A399Q34058486-B2D396C3-DFAF-45A8-BA77-D15DCF937360
P2860
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Standardization and quality co ...... Europe Against Cancer program.
@ast
Standardization and quality co ...... Europe Against Cancer program.
@en
type
label
Standardization and quality co ...... Europe Against Cancer program.
@ast
Standardization and quality co ...... Europe Against Cancer program.
@en
prefLabel
Standardization and quality co ...... Europe Against Cancer program.
@ast
Standardization and quality co ...... Europe Against Cancer program.
@en
P2093
P2860
P50
P356
P1433
P1476
Standardization and quality co ...... Europe Against Cancer program
@en
P2093
Beillard E
Cayuela JM
Cazzaniga G
De Micheli D
Grimwade D
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403135
P577
2003-12-01T00:00:00Z